NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...

Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Cipher Pharmaceuticals (CPHRF – Research Report) today and set a price ...

Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Savaria (SIS – Research Report) today and set a price target of ...

Gains in pharmaceutical and healthcare stocks such as Glenmark Lifesciences, Suven Pharma, others helped contain broader market losses on September 6 as investors showed buying interest in the ...

Emmy award-winning investigative reporter and New York Times bestselling author Sharyl Attkisson makes her case in her new book "Follow The Science: How Big Pharma Misleads, Obscures, and Prevails." ...

Denmark’s government expects the economy will expand 1.9% this year, cutting a previous forecast amid lower pharmaceutical export growth. The economy ministry cut its 2024 gross domestic product ...

NVG-291 is under clinical development by NervGen Pharma and currently in Phase II for Spinal Cord Injury. According to GlobalData, Phase II drugs for Spinal Cord Injury does not have sufficient ...

The “Pharma Bro” is done bringing the ruckus over a one-of-a-kind Wu-Tang Clan album. A federal judge this week ordered notorious price-gouging heel Martin Shkreli to turn over all copies of t ...

Alembic Pharmaceuticals Limited on Tuesday announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA ...

NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. NVG-291 is derived from the intracellular ...